KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accumulated Expenses (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Accumulated Expenses for 13 consecutive years, with $18.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 54.61% to $18.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.6 million, a 54.61% increase, with the full-year FY2025 number at $18.6 million, up 54.61% from a year prior.
  • Accumulated Expenses was $18.6 million for Q4 2025 at Xenon Pharmaceuticals, up from $11.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $18.6 million in Q4 2025 to a low of $1.3 million in Q1 2021.
  • A 5-year average of $6.3 million and a median of $5.4 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 107.76% in 2021, then fell 1.97% in 2022.
  • Xenon Pharmaceuticals' Accumulated Expenses stood at $5.9 million in 2021, then decreased by 1.97% to $5.8 million in 2022, then skyrocketed by 51.54% to $8.8 million in 2023, then skyrocketed by 36.68% to $12.1 million in 2024, then soared by 54.61% to $18.6 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Accumulated Expenses are $18.6 million (Q4 2025), $11.1 million (Q3 2025), and $8.5 million (Q2 2025).